AlloVir | Evaluate

December 09, 2020

Ash 2020 movers – shorts roasting on an open fire

IGM’s snowballing share price belies some other major Ash winners, and will make Christmas unhappy for funds that had shorted the stock.

November 26, 2020

Ash 2020 cell therapy preview – the battle for recognition

With many of the usual targets on display Fate, Celyad, Allovir and others look to maintain momentum.

October 01, 2020

Another huge quarter for biotech flotations

Drug developers raised a record $4.5bn in IPOs in the third quarter, and investor support for biopharma shows little sign of waning.